EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nuclear‐Localized BCKDK Facilitates Homologous Recombination Repair to Support Breast Cancer Progression and Therapy Resistance

Haiying Liu, Jiaqian Feng, Tingting Pan, Pinggen Zhang, Ling Ye, Zetan Jiang, Zilong Zhou, Qiankun Mao, Jian Li, Xinyi Yang, Ping Gao, De Huang und 1 weitere

Advanced Science · 2025

DOI: 10.1002/advs.202416590 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Haiying Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Science and Technology of …. Hauptthemen laut MEDLINE: Breast Neoplasms, Recombinational DNA Repair, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Strategic Priority Research Program of the Chinese Academy of Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Homologous recombination repair (HRR) is crucial for maintaining genomic stability by repairing DNA damage. Despite its importance, HRR's role in cancer progression is not fully elucidated. Here, this work shows that nuclear‐localized branched‐chain α‐ketoacid dehydrogenase kinase (BCKDK) acts as a modulator of HRR, promoting cell resistance against DNA damage‐inducing therapy in breast cancer. Mechanistically, this work demonstrates that BCKDK is localized in the nucleus and phosphorylates RNF8 at Ser157, preventing the ubiquitin‐mediated degradation of RAD51, thereby facilitating HRR‐mediated DNA repair under replication stress. Notably, aberrant expression of the BCKDK/p‐RNF8/RAD51 axis correlates with breast cancer progression and poor patient survival. Furthermore, this work identifies a small molecule inhibitor of BCKDK, GSK180736A, that disrupts its HRR function and exhibits strong tumor suppression when combined with DNA damage‐inducing drugs. Collectively, this study reveals a new role of BCKDK in regulating HRR, independent of its metabolic function, presenting it as a potential therapeutic target and predictive biomarker in breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsRecombinational DNA RepairDrug Resistance, NeoplasmHumansFemaleCell Line, TumorDNA DamageMiceAnimalsDisease ProgressionCell NucleusDNA-Binding ProteinsUbiquitin-Protein Ligases

Stichwörter der Autor:innen

BCKDKDNA repair inhibitorbreast cancercombinational therapyhomologous recombination repair

Substanzen

RNF8 protein, humanDNA-Binding ProteinsUbiquitin-Protein Ligases

Autor:innen und Institutionen

  • Department of General Surgery, The First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Science and Technology of China, Hefei, 230027, China.
  • Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Science and Medicine, University of Science and Technology of China, Hefei, 230027, China.
  • Medical Research Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510080, China.
  • Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, China.
  • Anhui Key Laboratory of Molecular Oncology, Hefei, 230026, China.
  • Institute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei, 230601, China.

ORCID-Profile: Huafeng Zhang

Förderung

  • National Key R&D Program of China
  • National Natural Science Foundation of China
  • Strategic Priority Research Program of the Chinese Academy of Sciences
  • Fundamental Research Funds for the Central Universities
  • Comprehensive National Science Center, Research Funds of Center for Advanced Interdisciplinary Science and Biomedicine of IHM
  • the Global Select Project of the Institute of Health and Medicine, Hefei Comprehensive National Science Center
  • National Key Research and Development Program of China

Zitieren

APA

Liu, H., Feng, J., Pan, T., Zhang, P., Ye, L., Jiang, Z., Zhou, Z., Mao, Q., Li, J., Yang, X., Gao, P., Huang, & Zhang, H. (2025). Nuclear‐Localized BCKDK Facilitates Homologous Recombination Repair to Support Breast Cancer Progression and Therapy Resistance. Advanced Science. https://doi.org/10.1002/advs.202416590

Vancouver

Liu H, Feng J, Pan T, Zhang P, Ye L, Jiang Z, et al. Nuclear‐Localized BCKDK Facilitates Homologous Recombination Repair to Support Breast Cancer Progression and Therapy Resistance. Advanced Science. 2025. doi:10.1002/advs.202416590

BibTeX
@article{Liu2025,
  author = {Liu, Haiying and Feng, Jiaqian and Pan, Tingting and Zhang, Pinggen and Ye, Ling and Jiang, Zetan and Zhou, Zilong and Mao, Qiankun and Li, Jian and Yang, Xinyi and Gao, Ping and Huang, De and Zhang, Huafeng},
  title = {Nuclear‐Localized BCKDK Facilitates Homologous Recombination Repair to Support Breast Cancer Progression and Therapy Resistance},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202416590}
}
Kostenlos starten →